BriaCell Therapeutics Corp. (NASDAQ:BCTX) Short Interest Update

BriaCell Therapeutics Corp. (NASDAQ:BCTX) saw a significant growth in short interest in October. As of October 15th, there was short interest totalling 727,600 shares, a growth of 62.0% from the September 30th total of 449,200 shares. Currently, 2.3% of the shares of the stock are sold short. Based on an average daily volume of 4,780,000 shares, the days-to-cover ratio is currently 0.2 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in BriaCell Therapeutics stock. Vontobel Holding Ltd. bought a new position in BriaCell Therapeutics Corp. (NASDAQ:BCTX) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned approximately 0.44% of BriaCell Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 15.42% of the company’s stock.

BriaCell Therapeutics Price Performance

Shares of BCTX traded up $0.01 on Monday, hitting $0.88. The company’s stock had a trading volume of 498,809 shares, compared to its average volume of 1,645,892. The company has a market capitalization of $16.06 million, a PE ratio of -0.69 and a beta of 1.34. BriaCell Therapeutics has a fifty-two week low of $0.46 and a fifty-two week high of $5.97. The company has a 50 day moving average price of $0.79 and a 200 day moving average price of $1.17.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of BriaCell Therapeutics in a report on Thursday, October 3rd.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.